JOHNSON & JOHNSON (JNJ) is a Health Care company in the Pharmaceutical Preparations industry (SEC CIK 0000200406). Annual revenue was $94.19B in FY2025, compared to $78.74B in FY2022. Net income in FY2025 was $26.80B (diluted EPS $11.03).
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY23Jan '23 | FY22Jan '22 |
|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Gross Profit | $63.94B | $61.35B | $5.67B | $8.46B | $8.58B |
| Operating Income | — | — | — | — | — |
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| EPS (Diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY23Jan '23 | FY22Jan '22 |
|---|---|---|---|---|---|
| Total Assets | $199.21B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY23Jan '23 | FY22Jan '22 |
|---|---|---|---|---|---|
| Operating Cash Flow | $24.53B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY23Jan '23 | FY22Jan '22 |
|---|---|---|---|---|---|
| Gross Margin | 67.9% | 69.1% |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000200406-26-000089 | Apr 23, 2026 | Apr 28, 2026 | Apr 27, 2026 21:33 UTC | EDGAR |
| 10-Q | 0000200406-26-000087 | Mar 29, 2026 | Apr 22, 2026 | Apr 22, 2026 20:02 UTC | EDGAR |
| 8-K | 0000200406-26-000076 | Apr 14, 2026 | Apr 14, 2026 | Apr 14, 2026 11:35 UTC | EDGAR |
| 10-K | 0000200406-26-000016 | Dec 28, 2025 | Feb 11, 2026 | Feb 11, 2026 21:06 UTC | EDGAR |
| 8-K | 0000200406-26-000002 | Jan 21, 2026 | Jan 21, 2026 | Jan 21, 2026 12:46 UTC | EDGAR |
| 10-Q | 0000200406-25-000209 | Sep 28, 2025 | Oct 22, 2025 | Oct 22, 2025 20:04 UTC | EDGAR |
| 8-K | 0000200406-25-000201 | Oct 14, 2025 | Oct 14, 2025 | Oct 14, 2025 11:22 UTC | EDGAR |
| 8-K | 0000200406-25-000190 | Sep 8, 2025 | Sep 9, 2025 | Sep 8, 2025 23:55 UTC | EDGAR |
Direct links to SEC EDGAR. JNJ has additional filings available on the SEC site.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $180.10B |
| $167.56B |
| $187.38B |
| $182.02B |
| Total Liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B |
|---|
| Stockholders' Equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B |
|---|
| Cash & Equivalents | $19.71B | $24.11B | $21.86B | $14.13B | $14.49B |
|---|
| Total Debt | — | — | — | — | — |
|---|
| $24.27B |
| $22.79B |
| $21.19B |
| $23.41B |
| Capital Expenditures | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B |
|---|
| Free Cash Flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B |
|---|
| 6.7% |
| 10.6% |
| 10.9% |
| Operating Margin | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% |
|---|
| Net Margin | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
|---|
| Return on Equity | 32.9% | 19.7% | 51.1% | 23.4% | 28.2% |
|---|
| Return on Assets | 13.5% | 7.8% | 21.0% | 9.6% | 11.5% |
|---|
| Debt / Equity | 1.52× | 1.44× | 1.44× | 1.44× | 1.46× |
|---|
